"Medical Speed Reading Society" Ping An Good Doctor Management Change Blood Sanofi China Region Adjustment

On May 19th, from 0 to 24 hours, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang Production and Construction Corps reported 5 new confirmed cases, including 1 case of imported overseas (in Inner Mongolia), 4 cases of local cases (all in Jilin); (Official website of the National Health and Health Commission)May 19, the province added 15 new asymptomatic infections, 10 cases, 26 cases of isolation, still under medical observation of asymptomatic infection 274 cases(Hubei Provincial Health and Health Commission)18, Xinhua was authorized to issue the "Cpc Central Committee of the State Council on the new era to speed up the improvement of the socialist market economic system." It mentions deepening the reform of the medical and health system, improving the unified medical insurance system for urban and rural residents and the insurance system for major diseases, improving the mechanism for the financing and adjustment of basic medical insurance, continuing to push forward the reform of the payment methods of medical insurance, and speeding up the implementation of the settlement system for medical treatment in different places()
18,《()》,3+6。 This proposed selection of a total of 19 enterprises, involving Johnson and Johnson Vision Kang, the United States Erkang, Abonod and other production enterprises(Seiber Blue Devices)Following the dismissal of Ping An Good Doctor son and CEO Wang Tao, 19, according to Caixin reported that the creation of Ping An Good Doctor's "Ali Department" executive team has also been all removed from office, by Ping An Group appointed the new management has been appointed to take overOn the same day, Ping An Good Doctor issued a supplementary announcement that Wang Tao, the former chairman, executive director and chief executive officer of the board of directors, had failed to meet the board's expectations in the performance of his management duties(Sina Pharmaceutical News)19, Sanofi announced a heavy news, China's regional organizational structure will be in line with the global structure, the implementation of the global business unit fully responsible for the implementation of the three core global business units of specialty drugs, generic drugs, vaccines to restructure the Business in China, and appointed the corresponding head18, Mersadon announced the appointment of Matthew Walsh and Rachel Stahler as chief financial officer and chief information officer of its new spin-off company, OrganonOrganon is a newly spun-off company dedicated to women's health, over-patented drugs and biosimilars that Mersadon announced on February 5(Pharmaceutical Rubik's Cube)recently, Haixiang Pharmaceuticals announced that it has received a written resignation report from director and general manager Yang SiweiYang Siwei applied to resign as a director and general manager of the company for personal reasonsOn the 19th, Haixiang Pharmaceuticals announced that it had appointed Sun Yang as general manager for the same term as the sixth term of the board of directors Seiber Blue 20, AstraZeneca and Mersadon announced that Lynparza has been approved in the United States for homologous recombination to repair gene mutations of metastatic resistant prostate cancer patients FDA approval is based on the results of a clinical phase III PROfound trial in which Lynparza had rPFS for 7.4 months in treatment of patients with BRCA1 and ATM mutations, compared with 3.6 months in the control group treated with abitron or enhemolyte Lynparza reduced the risk of disease progression or death by 66 percent (Pharmaceutical Ming Kang de) 20, CDE official website shows that Chengdu Cente 3 generic drug "phosphate oseltamivir cosuspender" listing application by the Drug Review Center (CDE) to undertake On April 2, Chengdu Cente has just submitted an application for the listing of class 4 generic drugs for oseltamivir phosphate capsules (CDE official website) Insight database shows that Zhengda Tianqing started 0.5 mg/2mL "inhalation with buddaed fluid" human bioequivalence test Previously, Tianqing has successfully taken 1mg/2mL specifications of the domestic first imitation, small specifications have not been approved (Insight Database) China Biopharmaceutical s19 announcement, the company and Kangfang biotechnology jointly developed and commercialized PD-1 mono-anti-amplimono, combined with The Arottini first-line treatment of advanced hepatocellular carcinoma clinical efficacy and safety Phase II research summary will be accepted in the form of posters at the 2020 ASCO Annual Meeting Arbutus Biopharma, of the Insight Database, recently published positive follow-up data for a Phase Ia/Ib clinical trial The data came from a single dose of 60mg AB-729, in which chronic HBV patients who were being treated with background nucleoside (acid) therapy received a single subcutaneous injection of 60mg dose AB-729 Data show that the 60 mg dose of single subcutaneous injection AB-729, significantly and lastingly reduced the surface antigen level of hepatitis B (Bio Valley) 18, Treasure Island announced that it will work with Guangzhou Hengnokang Pharmaceutical Technology Co., Ltd to jointly carry out the development, production and sales of HNC042 for injection Treasure Island will pay Hengnocon 150 million yuan mileage and annual net sales revenue of 6% of the sales commission Vividon Therapeutics, inc., announced that it has entered into a global exclusive license agreement with Roche to use its proteomics screening platform and proprietary small molecular database to develop new small molecule drugs targeting E3 connecting enzymes, as well as candidate drugs targeting oncology and immunological therapeutic targets The U.S FDA has awarded its next-generation sequencing accompanying diagnostic testing to breakthrough medical device setypes to detect the fusion of NTRK genes that cause cancer to form and grow, ArcherDX, Inc In addition, the company recently partnered with Bayer to develop an accompanying diagnostic product for Bayer's "no-go cancer" TRK inhibitor Vitrakvi Vitrakvi has been approved in the United States and the European Union for the treatment of patients with NTRK fusion mutations (Pharmaceutical Conde) Eiger recently announced that the U.S FDA has accepted Zokinvy's application for a new drug (NDA) The NDA seeks accelerated approval of Zokinvy for the treatment of premature aging and premature aging-like nuclear fibrosis The FDA has granted ZokinvyNDA priority review and has designated a target date for prescription drug user charges as November 20, 2020 The FDA has informed Eiger that it does not plan to convene an advisory committee meeting to discuss the NDA (Biovalley) 19, Fosun Pharma announced that its subsidiary Fuhong Hanhan litosimono-resistant biosimilar serotonin (Hanlikang) added 2 new applications for indications to the State Drug Administration, for: 1 primary treatment of litoxil lymphoma patients after litoxil mono-anti-chemotherapy after full or partial remission of single-drug maintenance treatment; (Pharmaceutical Rubik's Cube) Fujian Provincial Health Insurance Bureau on the 19th announced the "part of the 4 plus 7 pilot drug public inquiry to choose the results", Qilu Pharmaceutical's atoflavatine calcium tablets through the public inquiry to obtain the proposed qualification, Lipeketone tablets are the standard (Fujian Provincial Health Insurance Bureau)